Biotech Values

[DewDiligence]

isolution: Re: OXGN message #26,665:

>> [From the OXGN post]: To add some credibility to my post, her dosage is (30mg x % of body mass) for this phase; phase II is 40mg, and III is 50mg. <<

What the heck does this mean, specifically the references to phase II and phase III? Rather than strengthening the poster’s credibility as claimed, this passage reduces credibility somewhat in my view.

Given the small size of the trial (about 20 patients) and the description of the patient’s baseline and mid-course readings, the poster’s description would likely be sufficient to identify the patient. I find it a little hard to believe that a family member would place the patient in such a position by posting on Yahoo –particularly when the course of treatment is not yet completed.

I appreciate your heads-up regarding the OXGN post, but I have seen countless posts like this one on various Yahoo message boards which did not pan out, so I guess you can count me as a skeptic.

For the sake of the patients, I hope the OXGN post is true. Moreover, any press accounts of C4AP’s success in AMD would likely mention the clinical data for the closest competing drug, which happens to be Squalamine.

--
isolution, I greatly appreciate your posts here and hope you will continue to contribute. There is one thing I do not understand, however: your statement that you have no interest in “the financial results of GENR.” I would have thought that your insights into the science underlying Squalamine and the competing drugs would make you an eager investor in GENR at the current price. Regards, Dew